Prasanna Santhanam

Dr. Prasanna Santhanam


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AKArnaud D. Kaze
Arnaud D. Kaze
PSPrasanna Santhanam
Prasanna Santhanam
SMSolomon K. Musani
Solomon K. Musani
RARexford Ahima
Rexford Ahima
JEJustin B. Echouffo‐Tcheugui
Justin B. Echouffo‐Tcheugui
Background: Metabolic dyslipidemia (high triglyceride) and low high‐density lipoprotein cholesterol (HDL‐C) is highly prevalent in type 2 diabetes mellitus (T2DM). The extent to which diabetes mellitus–related abnormalities in the triglyceride–HDL‐C profile associates with cardiovascular disease (CVD) risk is incompletely understood. We evaluated the associations of triglyceride and HDL‐C status with CVD outcomes in individuals with T2DM. Methods and Results: We analyzed data from 4199 overweight/obese adults with T2DM free of CVD with available data on triglyceride and HDL‐C at baseline (2001–2004) in the Look AHEAD (Action for Health in Diabetes) study. We used Cox proportional models to estimate hazard ratios (HRs) and 95% CIs of: (1) composite CVD outcome (myocardial infarction, stroke, hospitalization for angina, and/or death from cardiovascular causes); (2) coronary artery disease events; and (3) cerebrovascular accidents (stroke). Of the 4199 participants, 62% (n=2600) were women, with a mean age of 58 years (SD, 7), and 40% (n=1659) had metabolic dyslipidemia at baseline. Over a median follow‐up of 9.5 years (interquartile range, 8.7–10.3), 500 participants experienced the composite CVD outcome, 396 experienced coronary artery disease events, and 100 experienced stroke. Low HDL‐C was associated with higher hazards of the composite CVD outcome (HR, 1.36; 95% CI, 1.12–1.64 [ P =0.002]) and coronary artery disease events (HR, 1.46; 95% CI, 1.18–1.81 [ P =0.001]) but not stroke (HR, 1.38; 95% CI, 0.90–2.11 [ P =0.140]). Compared with patients with normal triglyceride and normal HDL, participants with metabolic dyslipidemia had higher risks of the composite CVD outcome (HR, 1.30; 95% CI, 1.03–1.63 [ P =0.025]) and coronary artery disease events (HR, 1.48; 95% CI, 1.14–1.93 [ P =0.003]) but not stroke (HR, 1.23; 95% CI, 0.74–2.05 [ P =0.420]). Conclusions: In a large sample of overweight/obese individuals with T2DM, metabolic dyslipidemia was associated with higher risks of CVD outcomes. Our findings highlight the necessity to account for metabolic dyslipidemia in CVD risk stratification among patients with T2DM. Registration: URL: https://www.lookaheadtrial.org ; Unique identifier: NCT00017953 .

15 January 2021 in Endocrine
Verified
Journal Article
Closed access
PDF file
HMHaris Muhammad
Haris Muhammad
PSPrasanna Santhanam
Prasanna Santhanam
JRJonathon O. Russell
Jonathon O. Russell

28 February 2017 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
PSPrasanna Santhanam
Prasanna Santhanam
DTDavid Taieb
David Taieb
LSLilja Solnes
Lilja Solnes
WMWael Marashdeh
Wael Marashdeh
PLPaul W. Ladenson
Paul W. Ladenson

29 December 2017 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
KMKanaan Mansoor
Kanaan Mansoor
MKMurad Kheetan
Murad Kheetan
SSSaba Shahnawaz
Saba Shahnawaz
ASAnna P. Shapiro
Anna P. Shapiro
EPEva Patton-Tackett
Eva Patton-Tackett
ZKZeid J. Khitan
Zeid J. Khitan
The United States is faced with an unprecedented epidemic of drug abuse. Every year thousands of Americans visit the emergency departments all over the country with illicit drug related complaints. These drugs have been known to be associated with a range of renal pathologies, from reversible acute kidney injuries to debilitating irreversible conditions like renal infarction. So far, no comprehensive study or systematic review has been published that includes the commonly used street drugs and designer drugs with potential nephrotoxic outcomes. We conducted a systematic review of published case reports, case series, and cross sectional studies of nephrotoxicities related to drugs of abuse. Literature review was conducted using PubMed/Medline from January 1, 2005 -December 31, 2016 to search for publications related to drug abuse with a defined renal outcome. Publications which reported renal injury in relation to the use of illicit drugs were selected, specifically those cases with raised creatinine levels, clinically symptomatic patients, for instance those with oliguria and proven renal biopsies. A total of 4798 publications were reviewed during the search process and PRISMA flow chart and Moose protocol regarding systematic reviews were followed. 110 articles were shortlisted for the review. A total of 169 cases from case reports and case series, and 14 case studies were analyzed. Renal manifestations of specific illicit drug abuse were included in this review. Based on the evidence presented, a wide range of renal manifestations were found to be associated with drug abuse. If the trend of increasing use of illicit drug use continues, it will put a significant percentage of the population at an elevated risk for poor renal outcomes. This study is limited by the nature of the literature reviewed being primarily case reports and case series.

15 June 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AKArnaud D. Kaze
Arnaud D. Kaze
PSPrasanna Santhanam
Prasanna Santhanam
SESebhat Erqou
Sebhat Erqou
RARexford S. Ahima
Rexford S. Ahima
ABAlain Bertoni
Alain Bertoni
JEJustin B. Echouffo‐Tcheugui
Justin B. Echouffo‐Tcheugui
Background: Microvascular disease (MVD) is a potential contributor to the pathogenesis of diabetes mellitus–related cardiac dysfunction. However, there is a paucity of data on the link between MVD and incident heart failure (HF) in type 2 diabetes mellitus. We examined the association of MVD with incident HF in adults with type 2 diabetes mellitus. Methods and Results: A total of 4095 participants with type 2 diabetes mellitus and free of HF were assessed for diabetes mellitus–related MVD including nephropathy, retinopathy, or neuropathy at baseline in the Look AHEAD (Action for Health in Diabetes) study. Incident HF events were prospectively assessed and adjudicated using hospital and death records. Cox models were used to generate hazard ratios and 95% CIs for HF. Of 4095 participants, 34.8% (n=1424) had MVD, defined as the presence of ≥1 of nephropathy, retinopathy, or neuropathy at baseline. Over a median of 9.7 years, there were 117 HF events. After adjusting for relevant confounders, participants with MVD had a 2.5‐fold higher risk of incident HF than those without MVD (hazard ratio, 2.54; 95% CI, 1.73–3.75). This association remained significant after additional adjustment for interval development of coronary artery disease (hazard ratio, 2.42; 95% CI, 1.64–3.57). The hazard ratios for HF by type of MVD were 2.22 (95% CI, 1.51–3.27), 1.30 (95% CI, 0.72–2.36), and 1.33 (95% CI, 0.86–2.07) for nephropathy, retinopathy, and neuropathy, respectively. CONCLUSIONS: MVD is associated with an excess HF risk in individuals with type 2 diabetes mellitus after adjusting for other known risk factors. Our findings underscore the contribution of MVD to the development of diabetes mellitus–related HF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00017953.

2 December 2022 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
SCStanley M Chen Cardenas
Stanley M Chen Cardenas
PSPrasanna Santhanam
Prasanna Santhanam
LMLilah Morris-Wiseman
Lilah Morris-Wiseman
RSRoberto Salvatori
Roberto Salvatori
AHAmir H Hamrahian
Amir H Hamrahian
Myriad questions regarding perioperative management of patients on glucocorticoids (GCs) continue to be debated including which patients are at risk for adrenal insufficiency (AI), what is the correct dose and duration of supplemental GCs, or are they necessary for everyone? These questions remain partly unanswered due to the heterogeneity and low quality of data, studies with small sample sizes, and the limited number of randomized trials. To date, we know that although all routes of GC administration can result in hypothalamic-pituitary-adrenal (HPA) axis suppression, perioperative adrenal crisis is rare. Correlation between biochemical testing for AI and clinical events is lacking. Some of the current perioperative management recommendations based on daily GC dose and duration of therapy may be difficult to follow in clinical practice. The prospective and retrospective studies consistently report that continuing the daily dose of GCs perioperatively is not associated with a higher risk for adrenal crises in patients with GC-induced AI. Considering that oral GC intake may be unreliable in the early postoperative period, providing the daily GC plus a short course of IV hydrocortisone 25 to 100 mg per day based on the degree of surgical stress seems reasonable. In patients who have stopped GC therapy before surgery, careful assessment of the HPA axis is necessary to avoid an adrenal crisis. In conclusion, our literature review indicates that lower doses and shorter duration of supplemental GCs perioperatively are sufficient to maintain homeostasis. We emphasize the need for well-designed randomized studies on this frequently encountered clinical scenario.